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Abstract  
 
Background 
Concerns about teratogenicity and offspring complications limit use of lithium in pregnancy. We aimed to 
investigate the association between in-utero lithium exposure and risk of pregnancy complications, delivery 
outcomes, neonatal morbidity and congenital malformations. 
 
Methods 
Meta-analysis of primary data analyzed using a shared protocol. Six study sites participated: Denmark, Canada, 
Netherlands, Sweden, UK, and US, totaling 727 lithium-exposed pregnancies compared to 21,397 reference 
pregnancies in mothers with a mood disorder, but unexposed to lithium. 
 
Main outcome measures included: (1) pregnancy complications, (2) delivery outcomes, (3) neonatal 
readmission to hospital within 28 days of birth, and (4) congenital malformations (major malformations and 
cardiac malformations). Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were generated using 
logistic regression models. Site-specific prevalence rates and ORs were pooled using random-effects meta-
analytic models.    
 
Findings 
Lithium exposure was not associated with any of the pre-defined pregnancy complications or delivery 
outcomes. There was an increased risk for neonatal readmission in lithium exposed (27·5%) versus reference 
group (14·3%) (Pooled aOR1·62; 95% CI: 1·12–2·33). Lithium exposure during first trimester was associated 
with increased risk of major malformations (7·4% versus 4·3%; pooled aOR 1·71, 95% CI: 1·07–2·72). 
Similarly, more lithium exposed children had major cardiac malformations, albeit not stasticially significant 
(2·1% versus 1·6%; pooled aOR 1·54, 95% CI: 0·64–3·70). Limitations in our study include: Serum lithium 
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levels were not available, hence no analyses related to dose-response effects could be performed, and residual 
confounding from e.g. substance abuse cannot be ruled out.  
 
Interpretation  
Treatment decisions must weigh the potential for increased risks, considering both effct sizes and the precision 
of the estimates, in particular associated with first-trimester lithium use against its effectiveness at reducing 
relapse. 
 
Funding 
List of funders is provided in manuscript.  
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Introduction  
Lithium is an effective first-line pharmacological treatment for patients with bipolar disorder,1,2 with well-
documented effects in the acute and maintenance phases for both depressive and manic symptoms, as well as in 
suicide risk reduction.1,3,4 Lithium is also used as an adjunctive therapy for patients with unipolar depression,5 
and can reduce affective symptoms in schizophrenia and schizoaffective disorder.6  
 
Bipolar disorder affects ~ 2% of the population,7 including reproductive-age women,8 so knowledge about 
benefits and risks of lithium treatment in pregnancy is essential. Lithium treatment can reduce the risk for 
relapse both in pregnancy and in the postpartum period.9,10 However, concerns about teratogenicity, maternal- 
and offspring complications (e.g., renal or thyroid problems, preterm birth) limit its use. The specific concern 
related to congenital anomalies teratogenicity mainly relates to first-trimester lithium use. Here the embryo is 
most vulnerable to teratogens, as this is the period of organ formation including the heart. In animal studies 
lithium use in early pregnancy has been linked to abnormalities of the central nervous system, heart and blood 
vessels in the exposed fetuses.11,12 In humans, studies have similarly found increased risks of malformations,13-
16
 preterm birth and other pregnancy and neonatal complications,13,17-19 while other studies have not.1,20 Most 
previous studies had limited statistical power to detect significant effects, and others were subject to recall bias 
and poor consideration of important confounding variables.20,21  
 
Meta-analyses can improve the precision of estimates regarding the safety of in-utero exposure to lithium by 
increasing sample size. This was done in 2012, where a meta-analysis found that risk of Ebstein’s anomaly was 
not significantly elevated after lithium exposure in pregnancy.20 Importantly however, the authors cautioned 
that the strength of their conclusion was limited by the small number of cardiac malformation cases, and that 
further studies with larger numbers of cases would be needed to establish this result more definitively.  
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Accordingly, the aim of this study was to conduct a meta-analysis of data from six international cohorts to 
investigate the association between in-utero lithium exposure and risk of a broad set of maternal and perinatal 
outcomes. Definitions of exposures, outcomes, potential confounders, and statistical analyses were harmonized 
across sites a priori using a shared study protocol to reduce heterogeneity and bias. 
 
Methods 
 
Participating cohorts  
This study combined primary data from 6 cohorts using meta-analysis: three population-level register-based 
cohorts in Denmark, Sweden and Ontario, Canada, and three clinical cohorts (i.e., women under psychiatric 
secondary care) from the Netherlands, the United Kingdom, and the United States. A joint study protocol was 
created prior to dataset creation and analysis, including specific definitions for selection criteria, each included 
variable, and statistical analysis. Each study site obtained local ethical approval. All cohorts comprised 
pregnancies resulting in live-born singleton deliveries from 1997 to 2015, where health-related information was 
available both for the mother and for the infant (Table 1). Pregnancies in which mothers were prescribed known 
teratogenic medications in pregnancy (thalidomide, valproate, retinoids, antineoplastic drugs, misoprostol, and 
methotrexate) were excluded from the analysis. A detailed description of the identification of study population 
and years of inclusion in each study site is presented in eTable 1 in the supplement. 
 
Lithium exposure 
The lithium-exposed group comprised pregnancies with lithium exposure during the index pregnancy. For 
register-based cohorts, lithium exposure during pregnancy was defined as at least two dispensations of lithium 
during pregnancy that were dispensed any time from one month prior to conception until the delivery, or a 
single lithium dispensation during pregnancy when there was at least one other lithium dispensation within six 
months before or after this date. Dispensations of lithium were identified using the Anatomical Therapeutic 
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Chemical (ATC) Classification System code N05AN01 in Denmark and Sweden and the corresponding Drug 
Identification Numbers in Ontario, Canada. For clinical cohorts, medical records were used to define lithium 
use during pregnancy. For the lithium-exposed group, we did not require a documented psychiatric diagnosis, as 
non-psychiatric indications for lithium are rare.  
 
For analyses with specific focus on congenital malformations, we were interested in lithium exposure during 
early pregnancy, and we further defined lithium exposure in the first trimester as follows: For register-based 
cohorts: 1) At least two dispensations of lithium in the first trimester (from one month before the date of 
conception to 90 days of gestation); or 2) One dispensation in the first trimester with at least one other 
dispensation within 6 months before or after this date. For clinical cohorts: Medical records were used to define 
lithium use in the first trimester. 
 
 Mood disorder reference group 
The reference group comprised women with a known history of mood disorder (bipolar disorder or major 
depressive disorder) without exposure to lithium from 90 days before pregnancy until the delivery. For register-
based cohorts, maternal mood disorder was defined as at least one inpatient and/or at least two outpatient 
contacts for bipolar disorder (equivalent to the International Classification of Diseases, 10th revision (ICD-10) 
codes F30‒F31) or major depressive disorder (ICD-10 codes F32‒F33) from 2 years prior to the date of 
pregnancy to the delivery date. For clinical cohorts, maternal mood disorder was defined as any medical history 
of bipolar disorder or major depressive disorder before delivery.   
 
Outcomes of interest 
Outcomes of interest were selected based on theoretical risks for general medication exposure in pregnancy and 
prior research on lithium use specifically.13,20 Outcomes were divided into four subcategories: 1) Pregnancy 
complications,  identified in pregnancy or within 42 days after delivery, using hospital-based diagnoses for 
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preeclampsia (ICD-10 code O14), diabetes during pregnancy (ICD-10 code O24), fetal distress (ICD-10 code 
O68), and postpartum hemorrhage (ICD-10 code O72); 2) Labour and delivery outcomes, identified in hospital, 
including caesarean section (ICD-10 codes O82 and P03·4; surgical code KMCA), preterm birth (<37 weeks 
gestation), low birth weight (<2500g), and small for gestational age (i.e. a birth weight below the 10th 
percentile of birth weight by gestational age and sex); 3) Neonatal hospital admission to a special care baby unit 
in the first 28 days of life; 4) Congenital malformations excluding chromosomal abnormalities in the child 
diagnosed by age 1 year, including all singular and combined structural defects, syndromes, sequences, and 
associations, such as cardiovascular defects, neural tube defects hypospadias, and epispadias (ICD-10 codes 
Q00‒Q89, excluding minor malformations according to the EUROCAT Guide 1·4).22 Major cardiac 
malformations were defined as atrial and atrioventricular septal defects and Ebstein’s anomaly (ICD-10 codes 
Q20–Q26), but excluding atrial septal defect (ICD-10 code Q21·1) and patent ductus arteriosus (ICD-10 code 
Q25·0) in infants born prior to 37 weeks gestation.22  
 
Statistical analysis  
All study sites performed analyses independently according to a protocol established a priori. The site-specific 
prevalence rates and effect estimates were subsequently sent to Denmark, and combined by applying an 
aggregate level meta-analysis, because individual-level data could not be shared outside most jurisdictions as 
mandated by local ethical committees and regulations. At each site, all outcomes were modeled as binary 
variables (yes/no), and a binary logistic regression model was used to estimate odds ratios (ORs) and 95% 
confidence intervals (CIs) comparing the lithium-exposed group to the reference group. Due to a specific 
concern related to lithium exposure in the first trimester and congenital malformations, we estimated the ORs of 
major malformations and major cardiac malformations comparing lithium exposure in the first trimester group 
to the reference group. Odds ratios were adjusted for maternal age at delivery (in years), primiparity, calendar 
year of birth, and treatment with any other psychotropic medication during pregnancy according to ATC codes 
filed under N05 and N06 excluding N05AN01, from 1-month prior to pregnancy to the delivery (yes/no). Data 
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management and analyses were performed using SAS 9·4 (Canada and Sweden), Stata 13·1 (Denmark and 
UK), SPSS 20·0 (The Netherlands), and R package (US). 
 
For the meta-analysis, data from each individual analysis were double entered in EpiData 3·1. The meta-
analysis was performed using Stata 13·1. Site-specific prevalence rates and effect estimates were pooled using 
random-effects meta-analytic models. In random-effects models, the inverse of within-study variation combined 
with the between-study variation was used as the weight. The pooled prevalence rates of individual outcomes 
were computed using the program Metaprop.23 The 95% CIs of pooled prevalence rates were calculated using 
an exact binomial approach. Overall estimates were presented as forest plots with the pooled adjusted ORs 
(aORs) and 95% CIs. Heterogeneity was quantified using the I2 statistic (ranges from 0% to 100%), which 
describes the proportion of variability in the effect sizes attributable to heterogeneity between study sites.  
 
Sensitivity analyses  
To account for possible heterogeneity and estimate the influence of a single cohort on overall estimates, in a 
“leave-one-out approach”, we recalculated the pooled aORs leaving one cohort out of the analyses each time. 
To determine whether results were influenced by the type of data source, we repeated each meta-analysis by 
stratifying based on whether the source of data was register-based or clinical cohort.  
 
We conducted additional sensitivity analyses (post hoc) using Swedish and Danish data only to further explore 
the potential for residual confounding. First, we repeated the primary analyses and further adjusted for marital 
and education status, antiepileptic use during pregnancy (other than valproate as pregnancies exposed to this 
drug were excluded a priori), and treatment with other psychotropic drugs as individual covariates, including 
antidepressants, antipsychotics, benzodiazepines and hypnotics, and psychostimulants. Second, we compared 
outcomes between pregnancies exposed to lithium and those where mothers used lithium before or after, but not 
during, pregnancy. Third, to estimate whether the use of reference group with maternal mood disorder 
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represented an appropriate comparison group, we estimated the difference of relative risk of various adverse 
outcomes in lithium exposed children in comparison to two different reference groups: group with maternal 
diagnosis of mood disorder and group with maternal diagnosis of bipolar disorder. 
 
Ethical approval 
Each study site obtained local ethical approval. For meta-analysis, only site-specific aggregated data were 
sent to Denmark, and no personal identifiable information was shared among groups. 
 
Role of the funding source 
All investigators conducted the research independently. The funders had no role in study design and conduct of 
the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of 
the manuscript; and decision to submit the manuscript for publication. 
 
Results 
A total of 727 lithium-exposed pregnancies were identified (n=557, or 76·6% from register-based cohorts). 
Baseline sample characteristics are presented in Table 1. Women in the lithium exposure group were more 
likely to be older, nulliparous, and to have filled a prescription for a psychotropic medication other than lithium 
during pregnancy, compared to the reference group (N=21,397).  
 
Lithium use during pregnancy was not associated with preeclampsia (pooled prevalence of 1·8% in lithium-
exposed vs. 2·1% in reference group, pooled aOR=0·97, 95% CI: 0·52–1·80), diabetes in pregnancy (6·4% vs. 
5·4%, pooled aOR=1·20, 95% CI: 0·81–1·78), fetal distress (14·1% vs. 13·2%, pooled aOR=1·00, 95% CI: 
0·76–1·32), or postpartum hemorrhage (7·4% vs. 7·1%, pooled aOR=1·28, 95% CI: 0·64–2·57). No differences 
between the lithium-exposed group and the reference group were observed for caesarean section (26·5% vs. 
25·8%, pooled aOR=0·94, 95% CI: 0·66–1·33), preterm birth (13·1% vs. 10·0%, pooled aOR=1·24, 95% CI: 
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0·83–1·84), low birth weight (6·4% vs. 7·2%, pooled aOR=0·98, 95% CI: 0·72–1·35), or small for gestational 
age (7·5% vs. 9·3%, pooled aOR=0·90, 95% CI: 0·67–1·21). In-utero lithium exposure was associated with an 
increased risk of neonatal admission to a special care baby unit prior to 28 days of age (27·5% vs. 14·3%, 
pooled aOR=1·62, 95% CI: 1·12–2·33) (Table 2). Forest plots with site-level ORs of these pregnancy 
complications, delivery outcomes and neonatal admission are present in eFigures 1–3 in the Supplement.  
 
There were 51 lithium-exposed children (7·2%) and 856 children from reference group  (4·3%) with major 
malformations diagnosed by one year of age. Lithium exposure was not statistically significantly associated 
with increased odds of major malformation (pooled aOR=1·58; 95% CI: 0·90–2·79), nor major cardiac 
malformations (2·0% vs. 1·6%, pooled aOR=1·31, 95% CI: 0·50–3·47), but statistical heterogeneity was high 
(Table 2).  For example, in Denmark, lithium exposure was associated with both major malformation and major 
cardiac malformation risk, but this association was not observed in data from the other 4 sites (Figure 1a–1b). 
Of 727 lithium exposed children, 654 (90·0%) were exposed to lithium in the first trimester (eTable 2). In total, 
47 children from the lithium exposure in the first trimester group were diagnosed with major malformations and 
16 with major cardiac malformations. Lithium exposure was associated with an increased risk of major 
malformations (7·4% vs. 4·3%, pooled aOR=1·71, 95% CI: 1·07–2·72), but not major cardiac malformations 
(2·1% vs. 1·6%, pooled aOR=1·54, 95% CI: 0·64–3·70) (Figure 1c–1d), in comparison to the reference group 
of mood disorders. Note, that no Ebstein’s anomaly cases were observed in any of the participating study sites.  
 
The “leave-one-out approach” analyses demonstrated an overall stability of the main findings, except for the 
association between lithium exposure in the first trimester and major malformations. This latter relation became 
non-significant when each of Denmark, Sweden, and the USA were left out (eTable 3 in the Supplement). 
Pooled ORs from the register-based cohorts substantially overlapped those of the clinical cohorts, except for 
postpartum hemorrhage, where a strong relation was observed in clinical cohorts (pooled aOR=2·58, 95% CI: 
1·21–5·52) but not in register-based cohorts (pooled aOR=0·79, 95% CI: 0·41–1·51, eTable 4).  
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Results from additional analyses in a subgroup that included only the Danish and Swedish data were generally 
consistent with those of the main analysis. Adjustments for education status, marriage status, antiepileptic and 
psychotropic medication use during pregnancy did not differ from the main results (eTable 5). When lithium 
exposed pregnancies were compared to pregnancies where women were using lithium before and after 
pregnancy but not during pregnancy, results were also generally consistent with those of the main analysis. 
However, the odds of major malformations was elevated among children exposed to lithium in pregnancy 
(pooled aOR=2·09, 95% CI: 1·10–3·96), although this was not the case specifically for major cardiac 
malformations (pooled aOR=1·28, 95% CI: 0·13–12·39, Table 3). The relative risk of adverse outcomes in 
lithium exposed children were similar when comparing to the reference group with maternal diagnosis of mood 
disorder or to the reference group with maternal diagnosis of bipolar disorder, although the relative risk of 
neonatal readmission was attenuated to null when comparing to the reference group with maternal diagnosis of 
bipolar disorder (eFigure 4). 
 
Discussion 
With combined data from 6 countries using a harmonized protocol, in-utero exposure to lithium was not 
associated with statistically significantly increased risks for any of the pregnancy complications or delivery 
outcomes investigated. Lithium was associated with a significantly increased risk (~1·5 times, 27.5% vs. 
14.3%) for neonatal readmission within four weeks postpartum. We furthermore found that lithium exposure in 
the first trimester specifically was associated with an increased risk of major malformations, but not major 
cardiac malformations, although the latter was studied only among 16 cases. Across our analyses, results were 
robust to the majority of sensitivity analyses, including stratification by study design, a leave-one-out approach, 
and adjustment for additional variables in a sub-cohort including Swedish and Danish data only.  
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This study has multiple strengths, including improving statistical power and generalizability over previous 
research. Analyses were performed following a shared protocol established a priori to minimize heterogeneity 
related to selection criteria, exposure, outcome and covariate definitions, and statistical methodology. All data 
on lithium exposure were collected from data recorded prior to outcome occurrence, so the risk of recall bias 
was low. The potential for bias related to the analysis was further minimized since each site performed its own 
analyses independently, blind to the results from other sites. Our study also has limitations. First, we chose to 
only include pregnancies ending with live-born children due to lack of information on stillbirths at some study 
sites. If lithium use during pregnancy increases the risk of stillbirths or miscarriage,24 conditioning on live-born 
children could have led to underestimation of adverse effects, so this is a potential study limitation.25 Second, 
even with a large sample size, our study lacks power to study very rare events. This e.g. relates to cardiac 
malformations, with only 16 observed cases, with subsequent limited statistical power. Third, as with all 
observational studies, residual confounding, especially that due to the severity of the underlying maternal 
illness, substance or alcohol abuse, cannot be ruled out.26 Fourth, we examined multiple outcomes, so the 
potential for Type I error and chance findings cannot be excluded. Fifth, we did not use an active comparator 
approach, i.e., we did not directly compare lithium to other medications that are sometimes used for the 
treatment of bipolar disorder. Sixth, no available data on lithium serum levels prevented analyses related to any 
potential dose-response associations, and a relatively wide defined lithium exposure window can lead to 
misclassification of lithium exposure and have biased our results towards the null. Seventh, we cannot rule out 
that less severe adverse outcomes are more likely to be reported and recorded in the lithium-exposed 
pregnancies than in the pregnancies included in our defined reference group, due to a general concern about 
teratogenic effects. However, this would likely bias the results toward finding an effect, which we did not 
observe for most outcomes.  
 
Lithium use was not associated with any of the pre-defined pregnancy complications and adverse delivery 
outcomes in our study. That being said, mental illness itself has been associated with adverse pregnancy 
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outcomes including preterm birth and cesarean delivery, regardless of whether women were treated with any 
mood stabilizing medication (i.e., lithium, antiepileptics, and antipsychotic medications, or some combination 
thereof).27 This may explain why previous studies,13,17,18 with less rigorous control for confounding related to 
maternal mental illness, might have observed an increased risk for these outcomes associated with lithium, 
while our study did not. Across our analyses there was an increased risk for neonatal admission within 4 weeks 
in lithium-exposed infants. To our knowledge, this is not an outcome previously investigated for lithium 
exposure and results could be explained through different mechanisms. Lithium withdrawal after birth could 
directly lead to neonatal morbidity requiring admission to a special care baby unit, as could lithium exposure in 
lactation (which is not generally recommended). Furhter, the neonatal morbidity could be explained through the 
underlying maternal disorder (supplement eFigure 4) or be due to increased vigilance towards infants exposed 
to lithium with subsequent detection of neonatal morbidities in these newborns. This will require detailed 
prospective studies to disentangle.   
 
Most prior research on lithium in pregnancy has focused on congenital malformations including Ebstein’s 
anomaly,13,15,16,28 however there were major methodological limitations to previous research. Most data comes 
from small retrospective clinical studies, prone to over-reporting on malformed infants, lack of information on 
exposed children without adverse outcomes and lack of confounder control.29-31 Adding further to the 
complexities of any interpretation, cardiac malformations may be associated with maternal mental illness and 
other related factors in general, rather than with exposure to lithium.29 In our study, comparisons were made to 
pregnancies among women with mental illness, rather than to pregnancies among all women, because at least 
some adverse outcomes in offspring exposed to lithium during pregnancy may stem from factors other than the 
lithium exposure per se. In our first-trimester specific analysis, more neonates in the lithium-exposed group had 
major malformations (7·4%) compared to our mood disorder reference group (4·3%), indicating a statistically 
significant increased risk in the lithium group (pooled OR=1·71, 95% CI: 1·07–2·72). This finding was 
supported by the sensitivity analysis comparing malformation risk in children of women who were prescribed 
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lithium during versus around (but not during) pregnancy using Danish and Swedish data, where an increased 
risk of major malformations were detected. Additionally, risk of cardiac malformations in our meta-analysis 
was 2·1% vs. 1·6%, pooled aOR=1·54, 95% CI: 0·64–3·70. In comparison, concern about malformations after 
in-utero exposure to lithium was similarly supported by the results of a recent well-conducted U.S. study on 663 
infants by Patorno et al., where the absolute risk for cardiac malformations (2·4%) was similar to ours (2·1%). 
14
 In this study there was a significantly increased risk of overall malformations in newborns exposed to lithium 
in-utero, risk ratio: 1·37 (95% CI: 1·01–1·87), as well as an increased risk of cardiac malformations, risk ratio: 
1·65 (95% CI: 1·02–2·68).14 At this point, an increased risk for malformations associated with lithium exposure 
is suggested and due to the serious complications of these findings this should guide treatment decisions as well 
as future studies. An approach aimed at further pooling evidence across countries/study sites and presented 
results, could in the next years provide the evidence needed to quantify any magnitude of risk associated with 
lithium exposure in pregnancy.  
 
In our study an increased risk for congenital malformations attributable specifically to first-trimester lithium use 
was found, but our results and that of Paterno et al. jointly suggest that the absolute risk of malformations is 
much smaller than reported in earlier studies. Further, we observed an increased risk for hospital admission 
shortly after birth for lithium-exposed infants which requires further study. Overall, treatment decisions must 
weigh the potential for increased risks, considering both the specific effect sizes and the precision of the 
estimates, associated with lithium use in pregnancy and in particular first-trimester against its effectiveness at 
reducing relapse. 
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Table 1. Characteristics of the participating study sites, comparing lithium-exposed group to reference 
group with maternal diagnoses of mood disorder 
 
Study site (population, year) 
 
N 
 
Age (years) 
mean ± SD 
 
Primiparity, 
No. (%) 
 
Other 
psychotropic 
drugs, No. (%) 
Canada (register-based cohort, 2002–2013)     
 Lithium-exposed group 201  27·6 ± 5·7      84 (41·8)     170 (84·6) 
 Reference group 6,333 26·4 ± 6·0 2,012 (31·8) 3,467 (54·7) 
Denmark (register-based cohort, 1997–2012)     
 Lithium-exposed group 118 32·9 ± 5·0      67 (56·8)       92 (78·0) 
 Reference group 1,335 29·3 ± 5·7    651 (48·8)     810 (60·7) 
Sweden (register-based cohort, 2005–2013)     
 Lithium-exposed group 238 32·3 ± 5·2    123 (51·7)     184 (77·3) 
 Reference group 13,407 29·6 ± 5·9    6,395 (47·7)  8,648 (64·5) 
The Netherlands (Clinical cohort, 2000–2015)     
 Lithium-exposed group 115 34·0 ± 4·3       55 (47·8)       61 (53·0) 
 Reference group 88 32·7 ± 4·8      18 (20·5)       24 (27·3) 
United Kingdom (Clinical cohort, 2007–2013)     
 Lithium-exposed group 27 35·0 ± 4·7      16 (59·3)       16 (59·3) 
 Reference group 202 32·0 ± 5·7      83 (41·1)     131 (64·9) 
United States (Clinical cohort, 2004–2015)     
 Lithium-exposed group 28 29·1 ± 5·8            5 (17·9)       21 (75·0) 
 Reference group 32 29·4 ± 6·1         5 (15·6)       21 (65·6) 
Overall      
 Lithium-exposed group 727  31·3 ± 5·2     350 (48·1)      544 (74·8) 
 Reference group 21,397  28·7 ± 5·9  9,164 (42·8) 13,101 (61·2) 
       Abbreviation: SD = Standard Deviation 
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Table 2. Pooled prevalence rate and odds ratio of health outcomes in lithium-exposed group compared to reference group with maternal 
diagnoses of mood disorder a 
 
Health outcomes   
Lithium-exposed group 
 
 
Reference group 
 
Pooled adjusted OR 
(95% CI) in lithium-
exposed group versus 
reference group b 
 
 
 
I-
squared 
(%) 
 
Pooled 
N 
 
N with 
outcome 
 
Pooled 
prevalence with 
95% CI (%) 
 
Pooled 
N 
 
N with 
outcome 
 
Pooled prevalence 
with 95% CI 
(%) 
Pregnancy complications          
  Preeclampsia d 612 13 1·8 (0·1, 3·5) 21,309 187 2·1 (0·9, 3·2) 0·97 (0·52, 1·80) 0·0 
  Diabetes d 489 35 6·4 (4·1, 8·8)   7,990 512 5·4 (2·5, 8·2) 1·20 (0·81, 1·78) 0·0 
  Fetal distress c 727 90 14·1 (3·9, 24·2) 21,397 1,561 13·2 (4·0, 22·4) 1·00 (0·76, 1·32) 0·0 
  Postpartum hemorrhage d 489 38 7·4 (3·3, 11·6) 7,990 391 7·1 (3·7, 10·5) 1·28 (0·64, 2·57) 53·5 
Labour and delivery outcomes         
  Caesarean section c 727 201 26·5 (20·3, 32·6) 21,392 4,844 25·8 (20·9, 30·7) 0·94 (0·66, 1·33) 62·0 
  Preterm birth c 717 96 13·1 (10·6, 15·6) 21,397 1,949 10·0 (7·3, 12·7) 1·24 (0·83, 1·84) 49.7 
  Low birth weight c 719 50 6·4 (4·5, 8·2) 21,338 1,339 7·2 (4·6, 9·7) 0·98 (0·72, 1·35) 0·0 
  Small for gestational age e 692 58 7·5 (2·3, 12·8) 21,302 1,614 9·3 (1·5, 17·1) 0·90 (0·67, 1·21) 0·0 
Neonatal readmission < 28 days c 718 172 27·5 (15·8, 39·1) 21,158 2,625 14·3 (10·4, 18·2) 1·62 (1·12, 2·33) 56·6 
Congenital malformations in lithium 
exposure group 
        
  Major malformations d 693 51 7·2 (4·0, 10·4) 20,957  856 4·3 (3·7, 4·8) 1·58 (0·90, 2·79) 57·3 
  Major cardiac malformations d 693 17 2·0 (0·5, 3·6) 20,957  316 1·6 (1·0, 2·1) 1·31 (0·50, 3·47) 54·9 
Congenital malformations in lithium 
first trimester exposure group 
        
  Major malformations d 621 47 7·4 (4·0, 10·7) 20,957  856 4·3 (3·7, 4·8) 1·71 (1·07, 2·72) 34·8 
  Major cardiac malformations d 621 16 2·1 (0·5, 3·7) 20,957  316 1·6 (1·0, 2·1) 1·54 (0·64, 3·70) 43·0 
a
 95% confidence interval was calculated using an exact binomial approach in random-effects meta-analytic models; b adjusted for maternal age at delivery, primiparity, treatment 
with other psychotropic medication use during pregnancy, and calendar year of birth; c Data from 6 countries were available for this pooled estimate; d Data from 5 countries were 
available for this pooled estimate; e Data from 4 countries were available for this pooled estimate. 
Note that N changed for different outcomes as not all sites contributed to the calculation of all outcomes and not all subjects in individual site had information on all outcomes. 
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Figure 1a. Pooled adjusted odds ratio of major congenital malformations in lithium exposed pregnancies 
compared to reference pregnancies with maternal diagnosis of mood disorder 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth. 
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Figure 1b. Pooled adjusted odds ratio of major cardiac malformations in lithium exposed pregnancies 
compared to reference pregnancies with maternal diagnosis of mood disorder 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth. 
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Figure 2a. Pooled adjusted odds ratio of major congenital malformations in lithium first trimester 
exposure pregnancies compared to reference pregnancies with maternal diagnosis of mood disorder 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth. 
  
NOTE: Weights are from random effects analysis
Overall
Study
Denmark
The United States
Sweden
The Netherlands
Canada
ID
1.71 (1.07, 2.72)
odds
3.28 (1.74, 6.18)
1.72 (0.29, 10.27)
1.53 (0.85, 2.74)
1.03 (0.22, 4.78)
1.11 (0.56, 2.21)
ratio (95% CI)
100.00
%
28.61
6.13
31.07
8.01
26.18
Weight
I-squared=34.8%
  
1.1 .5 5 10
Lithium exposure in the first trimester and major malformationsFigure 2a
28 
 
Figure 2b. Pooled adjusted odds ratio of major cardiac malformations in lithium first trimester exposure 
pregnancies compared to reference pregnancies with maternal diagnosis of mood disorder 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth. 
NOTE: Weights are from random effects analysis
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Table 3. Pooled prevalence rate and odds ratio of health outcomes in lithium use during pregnancy group compared to lithium use around 
pregnancy group in sub-analyses based on data from Sweden and Denmark 
Health outcomes  Lithium exposure during pregnancy  
 
Lithium exposure around pregnancy  Pooled adjusted OR 
(95% CI) in lithium 
exposure during 
pregnancy versus around 
pregnancy a 
 
I-
square
d (%) 
 
Pooled 
N 
 
N with 
outcome 
 
Pooled prevalence 
with 95% CI (%) 
 
Pooled 
N 
 
N with 
outcome 
 
Pooled prevalence 
with 95% CI (%) 
Pregnancy complications b         
  Fetal distress 356 15 0·6 (0·0, 1·5) 597 16 1·7 (0·6, 2·7) 0·91 (0·35, 2·37) 3·5 
Labour and delivery outcomes         
  Caesarean section  356 97 26·4 (21·9, 31·0) 597 131 21·9 (18·6, 25·2) 1·02 (0·45, 2·34) 74·7 
  Preterm birth  356 46 12·9 (9·4, 16·4) 597 54 8·9 (6·6, 11·2) 1·44 (0·92, 2·26) 0·0 
  Low birth weight 356 26 7·2 (4·5, 9·9) 597 31 5·0 (3·2, 6·7) 1·22 (0·68, 2·17) 0·0 
  Small for gestational age 356 18 3·4 (1·6, 5·3) 597 27 4·3 (2·7, 6·0) 0·85 (0·32, 2·22) 43·8 
Neonatal readmission <28 days  356 77 20·9 (16·7, 25·1) 597 83 13·8 (11·0, 16·6) 1·65 (1·14, 2·41) 0·0 
Congenital malformations         
  Major malformations 356 31 7·1 (4·4, 9·7) 597 20 3·1 (1·7, 4·5) 2·09 (1·10, 3·96) 0·0 
  Major cardiac malformations 356 8 1·2 (0·1, 2·3) 597 9 1·5 (0·5, 2·4) 1·28 (0·13, 12.39) 52·1 
 
a
 adjusted for maternal age at delivery, primiparity, other psychotropic medication use during pregnancy, and calendar year of birth; b The number of preeclampsia, diabetes 
during pregnancy and postpartum hemorrhage cases were too small to calculate the pooled odds ratio. 
 
Lithium use around pregnancy (N=597): Mothers with lithium treatment within 1) a period from 400 days prior to the beginning of pregnancy (conception) until 122 days prior 
to the beginning of pregnancy, or 2) a period from after childbirth until 280 days after childbirth. Lithium treatment in either period were defined as either A) having least two 
lithium dispensations during the period, or B) one dispensation during the defined period and at least another dispensation within 6 months before or after this date (not 
overlapping pregnancy);  
Lithium exposure group (N=356): Mothers with at least two dispensations of lithium during pregnancy (from one month prior the date of conception to the delivery date), or one 
dispensation during pregnancy with at least one other dispensation within 6 months before or after this date. 
 
Note: As results in Table 3 are based on data from only Denmark and Sweden, the presented pooled N in each category is smaller than the presented pooled N in Table 2, which 
includes data from entire study base from six countries.  
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Appendix Tables and Figures 
 
eTable 1. The identification of study population in each study site 
Study site Study population 
Canada (Register-
based cohort, 2002–
2013) 
We drew our study cohort from the Institute for Clinical Evaluative Sciences (ICES), an independent, non-profit organization that holds 
health administrative data on all Ontario residents.1 Databases for outpatient visits, hospitalizations, prescription drug use, and 
sociodemographic data were linked at the individual level using a unique encrypted identifier and analyzed at ICES. The cohort comprised 
all 16- to 50-year-old female Ontario residents who had a singleton liveborn delivery after 20 weeks gestational age, with a conception date 
between April 1, 2002 and March 31, 2013, and who were eligible for Ontario’s publicly funded drug program. Eligibility for the publicly 
funded drug program was determined as having (1) filled at least 1 prescription under the Ontario Drug Benefit plan between 181-365 days 
prior to pregnancy and (2) filled at least 1 prescription under the plan from 180 days prior to pregnancy to 180 days subsequent to 
pregnancy. Women using known teratogenic medications (i.e., thalidomide, valproate, retinoid, antineoplastic agents, misoprostol, 
methotrexate) were excluded. Lithium exposure was identified as having at least two prescriptions from one month before conception until 
delivery or one prescription during pregnancy and another 6 months before after this date, using the following drug identification numbers: 
00461733, 02216132, 02242837, 02013231, 09857532, 00236683, 02216140, 02242838, 00406775, 09857540, 00590665, and 02266695. 
Bipolar and major depressive disorder were identified as having at least 1 hospitalization for bipolar disorder or major depressive disorder 
and/or two outpatient contacts with a diagnosis of bipolar disorder/major depressive disorder from 2 years prior to the date of conception to 
the delivery date (in hospitalization data: ICD-9 296, 311; ICD-10 F30-F33; in psychiatric hospitalization data: bipolar disorder, major 
depressive disorder; in outpatient data: 296, 311). We identified 201 women with lithium exposure in pregnancy and who also had a bipolar 
or major depressive disorder, 6,333 women without lithium exposure who had a bipolar or major depressive disorder. 
Denmark (Register-
based cohort, 1997–
2012) 
All liveborn and new residents in Denmark are assigned a unique Civil Personal Register number, which enables individual level linkage 
across registers. We drew our study cohort from the Danish Medical Birth Register,2 which holds data on all live births and their mothers 
since 1968. We identified 932,934 singletons born during Nov 1st, 1997 until Dec 31st, 2012 in Denmark. We excluded 6,639 children with 
missing or extreme gestational age and 581 children whose mothers used any known teratogenic medications during pregnancy. Of those 
581 children, 556 children were exposed to valproate acid in utero. After exclusion, 925,714 singletons were left in the cohort. To obtain 
information on maternal bipolar or major depressive disorder before delivery (ICD-10 codes F30‒F33) and lithium use during pregnancy 
(Anatomical Therapeutic Chemical Classification System (ATC) code N05AN01), we linked the Danish National Birth Cohort to the 
Danish National Prescription Registry3 and the Danish Psychiatric Central Research Register.4 The Danish National Prescription Register 
covers all prescriptions dispensed in Denmark since 1995. The Danish Psychiatric Central Research Register was established as an 
electronic database in 1969. The register holds information on all treatments at psychiatric hospitals and psychiatric wards in general 
hospitals since 1969. In 1995, data on emergency room visits and outpatient treatments was included. Altogether, 118 children born to 
mothers with lithium use during pregnancy and 1,335 to mothers with bipolar or major depressive disorders before delivery but with no 
lithium use during pregnancy were included.  
Sweden (Register-
based cohort, 2005–
2013) 
A birth cohort based on all liveborn singletons with gestational age information from October 1, 2005 to December 31, 2013 was 
established by linkage of Swedish National registers using the unique individual registration number.5 Mothers and offspring were 
identified in the Swedish Medical Birth Register that covers 99% of all births nationwide since 1973 and provides information on 
gestational age at birth that were used to calculate the duration of pregnancy.6 In Sweden, 95% of all pregnant women receive 
ultrasonography in the early second trimester, which provide the gestational age of the fetus with an error margin of ±7 days.7 Maternal 
bipolar or major depressive disorder before delivery were identified in the Swedish Patient Register.8 This register includes all psychiatric 
admissions since 1973 and outpatients since 2001, and provides admission dates along with the main and eight secondary diagnosis codes in 
accordance with the ICD codes, and bipolar or major depressive disorder were defines using ICD-10 codes F30‒F33. Medication use during 
pregnancy was identified in the Swedish Prescribed Drug Register that hold information on all dispensed prescription medications in 
Sweden since July 2005 along with medication name, prescription- and dispensation dates, and the ATC code.9 There were 702 children 
excluded whose mothers used any known teratogenic medications during pregnancy. The cohort included 632,089 children, with 238 
children born to mothers with lithium use during pregnancy and 13,407 to mothers with bipolar or major depressive disorders before 
delivery but with no lithium use during pregnancy.  
The Netherlands 
(Clinical cohort, 
2000–2015) 
The study was approved by the Institutional Review Board of the Erasmus University Medical Centre (MEC-2013-319 ABR). Women with 
bipolar spectrum disorders and/or lithium use during pregnancy referred to psychiatric/obstetric outpatient clinics in the Netherlands 
between 2000 and 2015 with live-born singleton deliveries were eligible for inclusion. Relevant obstetric and psychiatric data was extracted 
retrospectively from medical records and processed with data manager OpenClinica. We excluded 6 twin pregnancies, 4 pregnancies with 
an outcome of stillbirth (gestational age 22-39 weeks) and 6 pregnancies in which women used teratogenic medication; all six women used 
valproate in the first trimester. Together, 115 children born to mothers with lithium use during pregnancy were included. Of these, 77 
children were born in the Erasmus University Medical Centre, 35 children in Leiden University Medical Centre and n=3 children in other 
hospitals in the Netherlands. Further, 88 children born to mother with a bipolar spectrum disorder were included (Erasmus University 
Medical Centre (n=63), Leiden University Medical Centre (n=11) and other hospitals (n=14).  Of the included pregnancies, missing values 
were only present for birthweight (n=1) and Apgar scores (n=7). 
The United 
Kingdom (Clinical 
cohort, 2007–2013) 
We enrolled children of women who were treated by South London and Maudsley NHS Foundation Trust (SLAM) during their 
pregnancy.10 SLAM provides almost exclusive secondary mental health care to a catchment population of 1·2 million people in South 
London. The psychiatric records of all SLAM patients are accessible to researchers via an anonymized mental health research case registry 
(CRIS). CRIS allows structured field and free-text searches, supported by validated Natural Language Processing applications (e.g. for 
diagnoses and medication use). This database was linked to the national Hospital Episode Statistics (HES) database, which holds data on all 
hospital-based livebirths, and to the local Neonatal Badger dataset, which holds data related to admissions to local neonatal intensive care 
units. We identified 255 singletons born during the period Jan 1st 2007 to March 31st 2013 to women who met the following inclusion 
criteria: under the care of SLAM during pregnancy and either (a) took lithium during pregnancy (exposed group) or (b) did not take lithium 
during pregnancy and had an ICD-10 diagnosis of manic episode (F30), bipolar affective disorder (F31) or psychotic depression (F32·3, 
F33·3) (reference group). After excluding 26 children whose mothers used any known teratogenic medications during pregnancy, 229 
children were included in the cohort, comprising 27 children born to mothers with lithium use during pregnancy and 202 to mothers with 
bipolar disorder or psychotic depression before delivery but with no lithium use during pregnancy. 
The United States 
(Clinical cohort, 
2004–2015) 
The Carolina Data Warehouse for Health (CDW-H) is a central data repository containing clinical, research, and administrative data 
sourced from the University of North Carolina (UNC) Health Care System. It functions to aid with a number of research processes, 
including retrospective analyses. A request was made for a dataset of all women with an ever lithium prescription and an ever live-birth 
diagnosis. The CDW-H contains 2 databases: a pre-electronic medical record (EMR) database of limited clinical data from 2004-2013 and a 
post-EMR database with data from 2013-2015 where data was mined directly from individual EMRs. This resulted in a dataset of 103 
2 
 
women with 135 deliveries meeting criteria. Mother-child pairs are not linked in the UNC Health Care System so children had to be 
manually searched for using identifying clues in a mother’s record. It was not always possible to find the child as the mother may have 
delivered at UNC but then her child did not receive care at UNC and therefore did not have a record. This limitation resulted in the 
exclusion of 60 deliveries due to no or inadequate follow-up information on the child. Additionally, 2 deliveries were excluded due to a 
twin delivery; 8 deliveries were excluded due to no prior psychiatric history in the mother (bipolar or major depressive comparison 
pregnancies only) and 5 deliveries were excluded due to lithium exposure in the 90 days prior to delivery (bipolar or major depressive 
comparison pregnancies only). This resulted in 75 excluded deliveries. The sample included in the final analysis included 60 deliveries: 28 
lithium exposed pregnancies and 32 bipolar or major depressive comparison pregnancies. 
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eTable 2.  Percentage of lithium exposure in the first trimester in each study site 
 
Study site Lithium exposure during 
pregnancy 
Lithium exposure in the first 
trimester 
Percentage of first trimester 
exposure (%) 
Cananda 201 187 93.0 
Denmark 118 107 90.7 
Sweden  238 214 89.9 
The Netherlands 115 106 92.2 
The United Kingdom 27 26 96.3 
The United States 28 14 50.0 
Overall 727 654 90.0 
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eFigure 1. Pooled adjusted odds ratio of pregnancy complications in lithium-exposed group compared to reference group with maternal diagnoses of 
mood disorder  
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year of birth.
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eFigure 2. Pooled adjusted odds ratio of labour and delivery outcomes in lithium-exposed group compared to reference group with maternal diagnoses 
of mood disorder  
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year of birth.
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eFigure 3. Pooled adjusted odds ratio of neonatal readmission in the first 28 days of life in lithium-exposed group compared to 
reference group with maternal diagnoses of mood disorder  
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth.
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eTable 3. Pooled adjusted odds ratio of health in lithium-exposed group compared to reference group with maternal diagnoses of mood disorder using “leave-one-out 
approach” 
Health outcomes  Leave Canada out Leave Denmark out Leave Sweden out Leave the Netherlands 
out 
Leave the UK out Leave the USA out 
Pregnancy complications       
  Preeclampsia b 1·00 (0·48, 2·07) 1·08 (0·49, 2·38) 0·93 (0·48, 1·78) 0·97 (0·52, 1·80) 0·93 (0·48, 1·82) 0·96 (0·51, 1·84) 
  Diabetes b 1·15 (0·57, 2·33) 1·25 (0·82, 1·93) 1·20 (0·81, 1·78) 1·15 (0·77, 1·71) 1·17 (0·78, 1·77) 1·25 (0·84, 1·86) 
  Fetal distress a 1·03 (0·66, 1·61) 0·95 (0·70, 1·28) 1·02 (0·78, 1·35) 0·98 (0·74, 1·30) 1·05 (0·79, 1·39) 1·01 (0·76, 1·33) 
  Postpartum hemorrhage b 1·41 (0·50, 4·00) 1·67 (0·90, 3·09) 1·28 (0·64, 2·57) 1·09 (0·51, 2·33) 1·00 (0·51, 1·93) 1·34 (0·62, 2·87) 
Labour and delivery outcomes       
  Caesarean section a 0·83 (0·50, 1·38) 0·95 (0·63, 1·43) 0·81 (0·55, 1·21) 1·00 (0·70, 1·44) 0·91 (0·62, 1·35) 1·08 (0·83, 1·41) 
  Preterm birth a 1·38 (0·87, 2·19) 1·32 (0·81, 2·15) 1·07 (0·71, 1·63) 1·14 (0·76, 1·71) 1·21 (0·77, 1·89) 1·32 (0·91, 1·93) 
  Low birth weight a 1·16 (0·79, 1·69) 1·02 (0·72, 1·46) 0·80 (0·54, 1·19) 0·98 (0·71, 1·35) 0·97 (0·70, 1·34) 0·98 (0·71, 1·35) 
  Small for gestational age c 0·77 (0·48, 1·25) 0·96 (0·68, 1·34) 0·92 (0·67, 1·27) 0·90 (0·66, 1·21) 0·90 (0·67, 1·21) 0·90 (0·67, 1·21) 
Neonatal readmission< 28 days a 1·75 (1·09, 2·79) 1·66 (1·01, 2·71) 1·75 (1·06, 2·88) 1·37 (1·10, 1·71) 1·57 (1·05, 2·34) 1·72 (1·19, 2·50) 
Congenital malformations in lithium exposure 
group 
      
  Major malformations b 1·72 (0·83, 3·54) 1·20 (0·81, 1·80) 1·63 (0·75, 3·57) 1·68 (0·90, 3·15) 1·58 (0·90, 2·79) 1·64 (0·87, 3·08) 
  Major cardiac malformations b 1·63 (0·52, 5·12) 0·75 (0·35, 1·62) 1·63 (0·53, 4·97) 1·28 (0·42, 3.97) 1·31 (0·50, 3·47) 1·33 (0·40, 4·37) 
Congenital malformations in lithium first 
trimester exposure group 
      
  Major malformations b 2·01 (1·21, 3·32) 1·33 (0·88, 2·01) 1·74 (0·87, 3·47) 1·78 (1·05, 3·01) 1·71 (1·07, 2·72) 1·69 (0·99, 2·90) 
  Major cardiac malformations b 2·03 (0·77, 5·38) 0·93 (0·43, 2·00) 1·92 (0·70, 5·25) 1·52 (0·54, 4·23) 1·54 (0·64, 3·70) 1·44 (0·49, 4·19) 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year of birth;  
a Data from 6 countries were available for this pooled estimate;  
b
 Data from 5 countries were available for this pooled estimate;  
c
 Data from 4 countries are available for this pooled estimate. 
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eTable 4. Pooled adjusted odds ratio of health outcomes in lithium-exposed group compared to reference group with maternal 
diagnoses of mood disorder stratified on the design of the cohort 
Health outcomes  Register-based cohort Clinical cohort Total 
Pregnancy complications    
  Preeclampsia  0·92 (0·45, 1·86) 1·16 (0·32, 4·23) a 0·97 (0·53, 1·80) 
  Diabetes  1·16 (0·76, 1·78) a 1·43 (0·44, 4·69) a 1·20 (0·81, 1·78) 
  Fetal distress 1·03 (0·76, 1·39) 0·89 (0·45, 1·74) 1·01 (0·76, 1·32) 
  Postpartum hemorrhage 0·79 (0·41, 1·51) a 2·58 (1·21, 5·52) 1·28 (0·64, 2·57) 
Labour and delivery outcomes    
  Caesarean section  1·16 (0·88, 1·53) 0·58 (0·27, 1·23) 0·94 (0·66, 1·33) 
  Preterm birth  1·19 (0·76, 1·85) 1·33 (0·48, 3·71) 1·24 (0·84, 1·84) 
  Low birth weight 0·94 (0·60, 1·48) 1·17 (0·45, 3·00) 0·98 (0·72, 1·35) 
  Small for gestational age 0·90 (0·66, 1·21) - b 0·90 (0·67, 1·21) 
Neonatal readmission< 28 days  1·37 (1·09, 1·73) 2·09 (0·74, 5·91) 1·62 (1·12, 2·33) 
Congenital malformations in lithium exposure group    
  Major malformations 1·78 (0·87, 3·62) 0·97 (0·32, 2·93) a 1·58 (0·90, 2·79) 
  Major cardiac malformations 1·30 (0·31, 5·46) 1·22 (0·28, 5·39) a 1·31 (0·50, 3·47) 
Congenital malformations in lithium first trimester 
exposure group 
   
  Major malformations 1·78 (0·96, 3·30) 1·28 (0·70, 4·10) a 1·71 (1·07, 2·72) 
  Major cardiac malformations 1·39 (0·38, 5·07) 1·98 (0·43, 9·08) a 1·54 (0·64, 3·70) 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy and calendar year 
of birth;  
a Data from 2 countries were available for this pooled estimate;  
b
 Only data from the Netherlands was available. 
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eTable 5. Pooled adjusted odds ratio of outcomes in lithium-exposed group compared to reference group with maternal 
diagnoses of mood disorder in four different models on Danish and Swedish data 
Health outcomes  Model 1 a Model 2 b Model 3 c Model 4 d 
Pregnancy complications e     
  Preeclampsia  0·93 (0·39, 2·25) 0·93 (0·39, 2·24) 0·85 (0·35, 2·08) 0·90 (0·37, 2·23) 
  Fetal distress 1·00 (0·37, 2·68) 1·00 (0·38, 2·68) 1·04 (0·38, 2·84) 0·92 (0·30, 2·83) 
Labour and delivery outcomes     
  Caesarean section  1·14 (0·67, 1·94) 1·11 (0·61, 2·02) 1·11 (0·63, 1·97) 1·12 (0·73, 1·71) 
  Preterm birth  1·35 (0·76, 2·41) 1·40 (0·76, 2·57) 1·41 (0·80, 2·49) 1·44 (0·97, 2·13) 
  Low birth weight 1·14 (0·71, 1·83) 1·19 (0·72, 1·97) 1·17 (0·69, 1·97) 1·13 (0·74, 1·74) 
  Small for gestational age 0·75 (0·45, 1·24) 0·82 (0·49, 1·36) 0·81 (0·49, 1·34) 0·79 (0·47, 1·32) 
Neonatal readmission< 28 days 1·41 (1·08, 1·84) 1·44 (1·10, 1·88) 1·40 (1·07, 1·83) 1·37 (0·96, 1·97) 
Congenital malformations     
  Major malformations 2·17 (0·80, 5·90) 2·12 (0·82, 5·49) 2·06 (0·80, 5·29) 2·01 (0·71, 5·65) 
  Major cardiac malformations 1·78 (0·22, 14·31) 1·81 (0·24, 13·62) 1·87 (0·22, 16·03) 1·78 (0·18, 17·31) 
 
a
 model 1 adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy (yes/no), 
and calendar year of birth; 
b
 model 2 adjusted for the same factors as model 1, and further adjusted for education status and marriage status; 
c  model 3 adjusted for the same factors as model 2, and further adjusted for treatment with antiepileptic medication during pregnancy 
(any dispensation of a medication with ATC code filing under N03A, yes/no); 
d model 4 adjusted for maternal age at delivery, primiparity, calendar year of birth, education status, marriage status, and treatment 
during pregnancy with any medication according to: antidepressants (ATC codes filing under N06A, yes/no), antipsychotics (ATC 
codes filing under N05A or N05X, excluding N05AN01, yes/no), benzodiazepines and z-hypnotics (ATC codes filing under N05C, 
yes/no), psychostimulants (ATC codes filing under N05B, yes/no ), and antiepileptics (ATC codes filing under N03A, yes/no); 
e The number of diabetes during pregnancy and postpartum hemorrhage cases are too small to calculate the pooled odds ratio. 
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eFigure 4. Pooled adjusted odds ratio of outcomes in lithium-exposed group compared to reference group with maternal 
diagnosis of mood disorder and to reference group with maternal diagnosis of bipolar disorder on Danish and Swedish data 
 
Adjusted for maternal age at delivery, primiparity, treatment with other psychotropic medications during pregnancy (yes/no), and 
calendar year of birth; 
 
 
 
Research in context:  
 
Evidence before this study 
Pregnant bipolar disorder women have a significant risk of relapse both during pregnancy and 
postpartum. Lithium is an effective first-line pharmacological treatment for patients with bipolar 
disorder, but concerns about teratogenicity, maternal- and offspring complications limit its use in 
pregnancy. We searched PubMed for studies that investigated lithium use in pregnancy among 
women with mood disorders, (search performed July 3, 2017). Search terms applied were 
“lithium”, “pregnancy”, “bipolar”, “depression”, and “mood disorder”. After this, we identified 
additional papers by checking citations. For our search we considered only English language 
journals. Case studies were not included as references, but no further search terms or search 
restrictions were used as the existing evidence in the field is relatively limited.  
Mc Knight et al. conducted a systematic review and meta-analysis of studies published before 
October 2010 and found six case-control studies (n=264) on lithium use during pregnancy and 
risk of cardiovascular malformations. The odds of Ebstein’s anomaly did not differ significantly 
between lithium exposure cases and controls; however, estimates were unstable because of the 
low number of events, OR 0·27, 95% CI 0·004–18·17. After 2010, an observational study from 
Israel reported no increase in severe cardiovascular malformations in lithium exposed pregnancy.  
A recent well conducted study based on US data reported an increased risk of malformations 
after first-trimester exposure to lithium (RR 1·65,95% CI: 1·02–2·68), but with low absolute 
numbers of malformations. Other potential negative outcomes of lithium use were not 
investigated in this study. 
 
Added value of this study 
This meta-analysis analyzed new data from 6 countries, comparing 727 lithium-exposed and 
21,397 mood disorder control pregnancies. More neonates in the lithium-exposed group had 
major malformations compared to our mood disorder reference group, and analyses indicated a 
statistically significant increased risk of major malformations after first-trimester lithium use 
(aOR 1·71, 95% CI: 1·07–2·72). 
 
Our study found an increased risk of major malformations specifically after first-trimester 
exposure to lithium, as well as an increased risk of hospital admission in infants exposed to 
lithium across pregnancy. However, we did not find evidence of increased risk on other 
important maternal or infant outcomes such as preeclampsia, diabetes in pregnancy and fetal 
distress, as well as preterm birth, small for gestational age and low birth weight.  
 
Implications of all the available evidence 
Lithium treatment decisions are key and need to be encouraged prior to conception. In particular, 
first trimester lithium use should be cautioned and weighted based on the available evidence. To 
support a balanced decision making, women should be informed on malformation risk in first-
trimester exposed infants, but also about high relapse risks both during pregnancy and 
postpartum if lithium treatment is tapered during this sensitive period. Given the well 
documented effectiveness of lithium in reducing relapse in the perinatal period, one important 
clinical consideration in some patient groups is to restart lithium either after the first trimester or 
immediately postpartum.   
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Study protocol 
 
Maternal and infant outcomes associated with lithium use in pregnancy: Data from an 
international lithium collaboration in six countries 
 
Participants: Trine Munk-Olsen1,2; Xiaoqin Liu1; Alexander Viktorin3;  Hilary K. Brown4,5,6,7; Arianna Di Florio8,9; Brian 
M. D’Onofrio3,10; Tara Gomes7,11; Louise M. Howard12; Hind Khalifeh12; Holly Krohn9; Henrik Larsson3; Paul 
Lichtenstein3; Clare L. Taylor12; Inge Van Kamp13; Richard Wesseloo14; Samantha Meltzer-Brody9; Simone N. Vigod5,6,7; 
Veerle Bergink14 
 
Affiliations: 1 The National Center for Register-based Research, Aarhus University, Aarhus, Denmark; 2 Lundbeck 
Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark; 3 The Department of Medical Epidemiology 
and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 4 Interdisciplinary Centre for Health and Society, University of 
Toronto Scarborough, Toronto, Ontario, Canada; 5 Women’s College Research Institute, Women’s College Hospital, 
Toronto, Ontario, Canada; 6 Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; 7 Institute for 
Clinical Evaluative Sciences, Toronto, Ontario, Canada; 8 Division of Psychological Medicine and Clinical Neurosciences, 
Cardiff University, UK; 9 The Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, 
Chapel Hill, N.C, USA; 10 Department of Psychological and Brain Sciences, Indiana University, Bloomington, USA; 11 
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada; 12 Section of Women's Mental 
Health/Women's Health Academic Centre, Department of Health Service and Population Research, King's College London, 
Institute of Psychiatry, Psychology and Neuroscience, London, UK; 13 Department of Obstetrics, Section of Perinatal 
Psychiatry, Leiden University Medical Center, Leiden, The Netherlands; 14 The Department of Psychiatry, Erasmus Medical 
Centre, Rotterdam, The Netherlands 
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Study objective 
Lithium is an effective first-line pharmacological treatment for patients with bipolar disorder; however, concerns about 
adverse maternal and offspring outcomes related to lithium exposure during pregnancy limit its use in women of 
childbearing age. We, therefore, plan to perform a meta-analysis of primary data and results from Canada, Denmark, 
Sweden, the Netherlands, the United Kingdom, and the United States to investigate the association between lithium 
exposure during pregnancy and risk of pregnancy complications, delivery outcomes, neonatal morbidity and congenital 
malformations. 
 
Dataset creation 
Register-based cohorts:  
Definition of datasets in register-based cohorts in Canada, Denmark, and Sweden: Several important observation time 
windows must be determined: the entry and exit dates of the enrolment of the study population (Figure 1). To capture 
mothers with a psychiatric diagnosis, a minimum of 34 months lookback period before delivery (10 months during 
pregnancy and 2 years prior conception) in the hospital/psychiatric register is required. Similarly, to ensure a sufficient time 
window for defining lithium exposure and non-exposure, a minimum of 13 months is required (10 months during pregnancy 
and 3 months before conception) as the defined lookback period before the delivery. This information will be assessed 
through local prescription registers or similar data sources. To obtain the information on outcomes of interest, a minimum of 
one year follow-up time from delivery date is required.  
 
 
 
 
 
Figure 1 Timeframe for identifying study population  
 
Clinical cohorts:  
Definition of datasets in clinical cohort studies in the Netherlands, the United Kingdom, and the United States: The study 
population will be defined using the available recorded data parallel to the description above. Information on lithium use, 
maternal diagnosis of psychiatric disorders and outcomes of interest will be obtained from the medical records.  
 
Study population 
All liveborn singletons are eligible for inclusion in the study, but pregnancies with either of the following situations are 
excluded:  Pregnancies by mothers who were prescribed any known teratogenic medications during the index pregnancy (one 
filled prescription, or a clinical record of medication use from one month prior the date of conception to the 
delivery date). These include: thalidomide (ATC code: L04AX02), valproate (ATC code: N03AG01), retinoids 
(ATC code: D05BB), antineoplastic drugs (ATC code: L01), misoprostol (ATC code: A02BB01, G02AD06, and 
M01AE56), or methotrexate (ATC code: L01BA01 and L04AX03).   Children born with missing or likely errors in gestational age 
 
Definition of the exposure  
A different definition of lithium exposure will be used for register-based and clinical cohorts. See description below:  
Register-based cohorts: Information on lithium medication will be identified by using the Anatomical Therapeutical 
Chemical (ATC) Classification System code N05AN01 in Denmark and Sweden, and the Drug Identification Numbers 
(DINS) 00461733, 02216132, 02242837, 02013231, 09857532, 00236683, 02216140, 02242838, 00406775, 09857540, 
00590665, and 02266695 in Canada. Lithium exposure during pregnancy was defined as: 
 
1) At least two dispensations of lithium during pregnancy (from one month prior the date of conception to the delivery 
date); or  
2) One dispensation during pregnancy with at least one other dispensation within 6 months before or after this date.  
 
13 months for lithium 
use determination 
Observation Window—1 
year in the current stage 
Delivery date 
Max Follow-up Date 34 months for psychiatric 
disorders observation 
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Clinical cohorts: Lithium use during pregnancy was defined according to medical records. Information on lithium use can 
be collected both prospectively and retrospectively. To avoid recall bias, information on lithium exposure should be 
collected before the delivery date.   
 
Definition of bipolar or mood disorder reference group 
The reference group/category was defined as women with no dispensation of lithium from 90 days before conception to the 
delivery, but with at least one hospitalization for bipolar disorder (ICD-10 codes F30‒F31) or major depressive disorder 
(ICD-10 code F32‒F33) and/or two outpatient contacts (not including emergency room visit) with a diagnosis of bipolar 
disorder or major depressive disorder from 2 years before the date of conception to the delivery date. 
 
Definition of outcomes of interest  
Information on outcomes of interest can be extracted from different national registers, local or medical records. 
 
Pregnancy/obstetric complications 
Definitions:  We will investigate specific complications including preeclampsia, fetal stress, postpartum hemorrhage, 
gestational diabetes, gestational hypertension, and nausea/vomit. Postpartum hemorrhage is defined as the loss of more than 
500 ml of blood within the first 24 hours following childbirth. 
ICD-10 codes: Preeclampsia (O14), fetal stress (O68), postpartum haemorrhage (O72), diabetes mellitus during pregnancy 
(O24). 
Time of observation: During pregnancy or within 42 days after delivery 
 
Labour and delivery outcomes 
Definition: We will examine the following labor and delivery outcomes: cesarean section, preterm delivery, low birth 
weight, and small for gestational age. Gestational age is estimated on the basis of date of last menstrual period. Infants are 
classified as preterm delivery when they were born alive before 37 weeks’ gestation. Low birth weight is defined as a birth 
weight less than 2500 g. SGA is used as a proxy measure for fetal growth restriction. Small for gestational age (SGA) is 
defined as a birth weight below the 10th percentile of birth weight by the gestational age and sex, and large for gestational 
age (LGA) as above the 90th percentile. 
ICD-10 codes and surgery codes for cesarean section: ICD-10 codes O82 and P03.4; surgical codes KMCA 
Time of observation: At birth    
 
Neonatal readmissions 
Definition: Neonatal readmissions is defined as any medical condition resulting in inpatient hospital readmission, 
observational stay, or mortality in the first 28 days of life.  
Time of observation: 0‒28 days after birth  
 
Major congenital malformations and cardiac malformations 
Definition: Malformation is classified as major when it causes functional impairment, including all singular and combined 
structural defects, syndromes, sequences, and associations. Major cardiac malformations are defined as atrial and 
atrioventricular septal defects and Ebstein’s anomaly, excluding atrial septal defect and patent ductus arteriosus in infants 
born before 37 weeks gestation.1 
ICD-10 codes: Major malformations (Q00‒Q89 excluding codes for minor malformations listed in EUROCAT Guide 1.4);1 
major congenital heart defects (Q20–Q26, excluding Q21.1 and Q25.0 if gestational age<37 weeks).  
Time of observation: 0‒365 days after birth 
 
Statistical analysis 
Site-specific analysis 
All analysis will be conducted using Stata (StataCorp, College Station, TX, USA), SAS (SAS Institute Inc., Cary, NC, 
USA), or equivalent statistical software. All outcomes will be binary variables (yes/no), and binary logistic regression 
model will be used to estimate odds ratios (ORs) and their respective 95% confidence intervals (CIs) of various adverse 
outcomes in pregnancies exposed to lithium, in comparison to pregnancies by mothers with bipolar disorder or major 
depressive disorder and who did not take lithium during the index pregnancy (i.e. mood disorder reference group). 
 
5 
 
Considering limited statistical power, we will only adjust for essential confounders such as maternal age at delivery 
(continuous variable), primiparity (yes/no), calendar year of birth (three categories according to the distribution of data in 
each study site), and other psychotropic medication use during pregnancy (yes/no). Other psychotropic medication use 
during pregnancy is defined as ATC codes N05 and N06 excluding N05AN01 from 1-month before conception to the 
delivery.  
 
Site specific analyses will be performed locally by members of the local research team collaborting on the project. No group 
will share and disclose results with each other, but only provide results to the Danish group for meta-analytic purposes.  
 
Meta-analysis  
For the meta-analysis, data from each individual site will be double entered in EpiData 3.1. The meta-analysis will be 
performed using Stata 13.1. We will pool the site-specific prevalence rates and effect estimates using random-effects meta-
analytic models. The pooled prevalence rates of individual outcomes will be computed using the program Metaprop,2 and 
the 95% CIs will be calculated using an exact binomial approach. We will present overall estimates as forest plots with the 
pooled adjusted ORs (aORs) and 95% CIs. Heterogeneity will be quantified using the I2 statistic (ranges from 0% to 100%).  
 
The meta-analysis will be performed in Denmark by local members of the research team. After analyses have been 
performed results will be shared with the entire research group for discussion.  
 
Sensitivity analyses 
To test the robustness of our findings, we will perform the following two sensitivity analyses: First, to estimate the influence 
of a single cohort on overall estimates, in a “leave-one-out approach” we will recalculate the pooled adjusted ORs leaving 
one cohort out of the analyses each time. This will be done to ensure how results from individual groups potentially can 
drive the pooled estimates from the meta-analysis. Second, to determine whether results will be influenced by the data 
sources, we will repeat each meta-analysis by stratifying on the source of data (register-based versus clinical cohort). This 
will be done to ensure how results from specific datasets potentially can drive the pooled estimates from the meta-analysis.  
Presentation of the results 
Each study site will need to provide the following information on the study population. 
For clinical cohort:   How were the study subjects (i.e., the mother-child pairs) enrolled?   What were the inclusion and exclusion criteria?   How many pregnant women were invited to this study and what is the participation rate?   What were the response rates at delivery and 1 year after delivery?  Were the pregnant women chosen from a cohort designed for other study objectives? If yes, what were the 
objectives of this study? Please include relevant references available. 
For register-based cohort:   How was this study population identified?   What were the inclusion and exclusion criteria?   What was the coverage of the study population, i.e., the whole study population or provincial?   Which registers were used and how were they linked? Please provide relevant references.  How was information on lithium use and the diagnosis of bipolar or major depressive disorders obtained, for 
instance, the use of ICD codes, ATC codes, or drug Identification Numbers?  
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Table 1 (empty table to demonstrate how results will be presented). Baseline characteristics among women exposed 
to lithium during pregnancy and mood disorder reference group  
 
Study site (population, year) 
 
N 
 
Age (years) 
mean ± SD 
 
Primiparous, 
N (%) 
 
Other psychotropic 
drugs, N(%) 
Canada (register-based cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
Denmark (register-based cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
Sweden (register-based cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
The Netherlands (clinical cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
United Kingdom (clinical cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
United States (clinical cohort, study period)     
   Lithium-exposed group     
   Mood disorder reference group     
Overall      
   Lithium-exposed group     
   Mood disorder reference group     
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Table 2 (empty table to demonstrate how results will be presented). Odds ratio of adverse pregnancy/obstetric 
complications in lithium-exposed group compared to reference group with maternal diagnoses of mood disorder  
Timing of lithium use N Cases 
(%)  
Crude OR (95% CI) Adjusted OR (95% CI) 
Preeclampsia      
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Gestational diabetes     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Fetal stress     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Postpartum hemorrhage     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Adjusted for maternal age at delivery, parity, calendar year of birth, and other psychotropic medication use during 
pregnancy  
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Table 3 (empty table to demonstrate how results will be presented). Odds ratio of adverse labor and delivery 
outcomes in lithium-exposed group compared to reference group with maternal diagnoses of mood disorder  
Timing of lithium use N Cases  
(%) 
Crude OR 
(95% CI) 
Adjusted OR (95% 
CI) 
Caesarean section     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Preterm birth     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Low birth weight     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Small for gestational age     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Adjusted for maternal age at delivery, parity, calendar year of birth, and other psychotropic medication use during 
pregnancy  
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Table 4 (empty table to demonstrate how results will be presented). Odds ratio of neonatal readmissions in lithium-
exposed group compared to reference group with maternal diagnoses of mood disorder 
Timing of lithium use  N Cases 
(%)  
Crude OR 
(95% CI) 
Adjusted OR (95% 
CI) 
Neonatal readmissions     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Adjusted for maternal age at delivery, parity, calendar year of birth, and other psychotropic medication use during 
pregnancy  
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Table 5 (empty table to demonstrate how results will be presented). Odds ratio of major congenital malformations 
and cardiac malformations in lithium-exposed group compared to reference group with maternal diagnoses of mood 
disorder 
Timing of lithium use N Cases (%) Crude OR  
(95% CI) 
Adjusted OR (95% 
CI) 
Major malformations     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Major cardiac malformations     
  Mood disorder reference group  
  
1(ref) 1(ref) 
  Lithium-exposed group 
    
Adjusted for maternal age at delivery, parity, calendar year of birth, and other psychotropic medication use during 
pregnancy  
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STROBE Statement—Checklist of items that should be included in reports of cohort studies  
 
 Item 
No Recommendation 
Page No 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 1, 4-5 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found 
 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 6 
Objectives 3 State specific objectives, including any prespecified hypotheses 7 
Methods 
Study design 4 Present key elements of study design early in the paper 7 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-
up, and data collection 
7-9 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe 
methods of follow-up 
7 
(b) For matched studies, give matching criteria and number of exposed and unexposed  
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
7-10 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group 
7-9, eTable 
1 
Bias 9 Describe any efforts to address potential sources of bias 9-11 
Study size 10 Explain how the study size was arrived at 7, 22, 
eTable 1 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why 
9-11 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 9-11 
(b) Describe any methods used to examine subgroups and interactions  
(c) Explain how missing data were addressed  
(d) If applicable, explain how loss to follow-up was addressed  
(e) Describe any sensitivity analyses  
Results 
 
Participants 13* (a) Report numbers of individuals at each stage of study—e.g. numbers potentially eligible, examined 
for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
11, 22, 
eTable 1 
(b) Give reasons for non-participation at each stage  
(c) Consider use of a flow diagram  
Descriptive data 14* (a) Give characteristics of study participants (e.g. demographic, clinical, social) and information on 
exposures and potential confounders 
11, 22 
(b) Indicate number of participants with missing data for each variable of interest  
(c) Summarise follow-up time (e.g., average and total amount)  
Outcome data 15* Report numbers of outcome events or summary measures over time 11-12, 23, 26 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included 
11-13, 23-
26 
(b) Report category boundaries when continuous variables were categorized  
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period  
Other analyses 17 Report other analyses done—e.g. analyses of subgroups and interactions, and sensitivity analyses 12-13, 26, 
eTable 2-
5, eFigure 
1–4 
Discussion 
Key results 18 Summarise key results with reference to study objectives 13 
 2 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both 
direction and magnitude of any potential bias 
13 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, 
results from similar studies, and other relevant evidence 
13-16 
Generalisability 21 Discuss the generalisability (external validity) of the study results 13 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original 
study on which the present article is based 
17-18 
 
*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
